证券代码：300109 证券简称：新开源 公告编号：2025-027 博爱新开源医疗科技集团股份有限公司 关于 2023 年限制性股票激励计划第二个归属期限制性股票 归属结果暨股份上市公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 5、归属安排 | 归属安排 | 归属期间 | 归属比例 | | --- | --- | --- | | 第一个归属期 | 自授予之日起12个月后的首个交易日起至授 予之日起24个月内的最后一个交易日当日止 | 30% | | 第二个归属期 | 自授予之日起24个月后的首个交易日起至授 | 30% | 本激励计划授予的限制性股票的归属安排如下： 本次归属日：2025 年 7 月 2 日 本次归属股票数量：135.00 万股 本次归属人数：1 人 | | 予之日起36个月内的最后一个交易日当日止 | | | --- | --- | --- | | 第三个归属期 | 自授予之日起36个月后的首个交易日起至授 | 20% | | | 予之日起48个月内的最后一个交易日当日止 | | | 第四个归属期 | 自授予之日起48个 ...

证券代码：300109 证券简称：新开源 公告编号：2025-026 公司董事赵威先生收到中国证券监督管理委员会（以下简称"中国证监会"）的《立 案告知书》（编号：证监立案字0122025004号），根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，中国证监会决定对赵威先生因涉嫌 短线交易予以立案。 告知书》（〔2025〕1号），具体内容详见公司于2025年4月3日披露的《关于公 司董事收到行政处罚事先告知书的公告》（公告编号：2025-005）。 公司近日收到赵威先生的通知，获悉其已收到中国证监会河南监管局下发的 《行政处罚决定书》（〔2025〕2号）（以下简称《决定书》），现将相关情况 公告如下： 一、《行政处罚事决定书》主要内容 当事人:赵威，男，1965年5月出生，博爱新开源医疗科技集团股份有限公司 (以下简称新开源)董事，住址:辽宁省抚顺市新抚区。 依据《中华人民共和国证券法》(以下简称《证券法》)有关规定，我局对赵 威短线交易新开源股票案进行了立案调查，依法向当事人告知了作出行政处罚的 事实、理由、依据及当事人依法享有的权利，当事人未提出陈述、申辩意见，也 未要求听证。本案现已 ...

证券代码：300109 证券简称：新开源 公告编号：2025-026 博爱新开源医疗科技集团股份有限公司 关于公司董事收到《行政处罚决定书》的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司""新开源"）于2025 年1月21日披露了《关于公司董事收到立案告知书的公告》（公告编号：2025-002）， 公司董事赵威先生收到中国证券监督管理委员会（以下简称"中国证监会"）的《立 案告知书》（编号：证监立案字0122025004号），根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，中国证监会决定对赵威先生因涉嫌 短线交易予以立案。 2025年4月1日，赵威先生收到中国证监会河南监管局下发的《行政处罚事先 告知书》（〔2025〕1号），具体内容详见公司于2025年4月3日披露的《关于公 司董事收到行政处罚事先告知书的公告》（公告编号：2025-005）。 公司近日收到赵威先生的通知，获悉其已收到中国证监会河南监管局下发的 《行政处罚决定书》（〔2025〕2号）（以下简称《决定书》），现将相关情 ...

Core Viewpoint - The opening of the new R&D transformation production base by Xin Kai Yuan in Songjiang marks a significant milestone for the company and contributes to the development of the biopharmaceutical industry in the region [2][3][4] Group 1: Company Overview - Xin Kai Yuan is the first domestic high-tech enterprise focused on the production, R&D, and sales of PVP series products and PVME/MA series products, with over 1,000 clients globally [2] - The company has been planning its medical business headquarters in Shanghai Songjiang since 2018, aiming to strengthen its existing precision medicine and women's health businesses [2] - Xin Kai Yuan collaborates deeply with its invested companies, Huada Bio and Yongtai Bio, to establish a fully autonomous CAR-T cell production base with complete intellectual property rights [2] Group 2: Industry Impact - The establishment of the "Yuan Yin Nuo Fang" biopharmaceutical incubator and the signing of a commercial production base agreement for CAR-T cell drugs with Huada Bio will enhance production efficiency and reduce costs [3] - The new base aligns with the strategic goals of the Songjiang District, which aims to create a world-class biopharmaceutical industry cluster, thereby boosting R&D capabilities in cutting-edge fields like cell therapy and gene technology [3] - The operation of the new base is expected to drive innovation and international development in precision medicine and high-end fine chemicals in China [3][4]

Group 1 - The core viewpoint of the news is that XinKaiYuan's stock price surged due to the announcement of a clinical trial approval for a new drug, LYC001, developed by its affiliate, marking a significant milestone in innovative drug development [1][3] - XinKaiYuan's stock price reached 19.18 yuan per share, approaching the daily limit, and closed with an increase of over 3% [1] - The drug LYC001, a high-affinity complex, is the first of its kind globally to utilize a novel drug delivery technology through the lymphatic system, addressing issues of stability and specificity in existing large molecule drugs [1][2] Group 2 - The clinical trial approval for LYC001 is a key milestone for the company, as it is part of a national key research and development program focused on innovative drug technology for common diseases [1][3] - The drug demonstrates significant advantages, including improved solubility and stability of interleukin-2, with a biological availability exceeding 90% when administered subcutaneously [2] - XinKaiYuan holds a 23.81% stake in the affiliate, and the progress in drug development is expected to strengthen its competitive position in the precision medicine sector [3]

Company Announcements - Dongfang Electric Heat signed a strategic cooperation agreement with Xiaomi's subsidiary Shanghai Zhishi to actively develop robotic electronic skin [2] - Chengdu Huami launched a 4-channel, 12-bit, 16G high-speed high-precision RF direct sampling ADC chip, marking a significant breakthrough in high-speed data conversion technology [4] - Vanke A sold 22 million A-share treasury stocks for a total of 146 million yuan, which will help supplement the company's liquidity [5] - Honghe Technology's stock will resume trading as Hefei Ruicheng is set to become the company's indirect controlling shareholder [8] Strategic Partnerships - Beizhi Technology reached a strategic cooperation intention with Xingdong Jiyuan to collaborate on humanoid robots in smart logistics applications [3] - Redik plans to acquire 51% of Yuzhan Precision, focusing on the application of micro-screw technology in robotic dexterous hands [19] Financing and Capital Increase - Fangzheng Technology plans to raise no more than 1.98 billion yuan through a private placement to fund the AI and high-density interconnect circuit board industry [17] Shareholding Changes - Guangting Information intends to purchase 100% of Kaima Technology for 360 million yuan, aiming to enhance its market position [19] - Qu Mei Home's director reduced holdings by 58,000 shares during a period of abnormal stock trading [4] Market Reactions - Jinshi Technology clarified that it has not engaged in any business related to stablecoins, despite a significant stock price increase of 76.51% [11] - Jinying Co. announced it is not involved in solid-state battery business, with its lithium battery materials revenue being only 1.70% of total revenue [12]

Core Viewpoint - The announcement highlights that the company's affiliate, Beijing Liangyuan Biopharmaceutical Research Co., Ltd., has received implied approval for clinical trials of its injectable human interleukin-2 (high-affinity complex) for the treatment of advanced solid tumors, marking a significant advancement in the field of precision medicine in China [1] Company Summary - The product is the first globally to utilize a high-affinity hierarchical assembly technology platform for the development of a new drug targeting various solid tumors, showcasing innovation in the biopharmaceutical sector [1] - The company holds a 23.8095% stake in Liangyuan Biopharmaceutical, indicating a strategic investment in promising biopharmaceutical developments [1] - This research progress is expected to strengthen the company's leading position in the precision medicine field and enhance its core competitiveness [1]

证券代码：300109 证券简称：新开源 公告编号：2025-025 博爱新开源医疗科技集团股份有限公司 关于参股公司注射用人白介素-2（高亲和型复合物）在中国获 批临床的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）参股公司北京良 远生物医药研究有限公司（简称"良远生物"）研发的注射用人白介素-2（高亲和 型复合物）获得国内临床试验默示许可，适应症为晚期实体瘤，具体内容如下： 一、产品基本信息 名称：注射用人白介素-2（高亲和型复合物） 受理号：CXSL2500248 药品类型：治疗用生物制品 申请类型：新药 该技术平台是全球首创的通过淋巴系统给药的药物递送技术，解决了现有大 分子药物通过血液循环进行分布而导致的稳定性低、特异性差等问题。本品为该 技术平台的首个产品，获批临床试验是关键里程碑事件。本品的开发入选 2023 年度国家重点研发计划"常见多发病防治研究"重点专项（间叶间皮神经系统来源 恶性肿瘤创新药物技术研发及精准递送平台建立）。 LYC001 的技术优势包括： （1）具有明显的层级结构 ...

Company Overview - The company, Boai New Kaineng Medical Technology Group Co., Ltd., specializes in fine chemicals and precision medicine, with key products including PVPK30, PVP-I, PVP series, and early cancer diagnosis services [1] - The latest financial report indicates that for Q1 2025, the company achieved a revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit of 80.42 million yuan, down 33.75%, with a gross profit margin of 44.07% [1] Market Performance - As of June 9, the company's stock closed at 17.83 yuan, reflecting an increase of 2.77%, with a rolling price-to-earnings (PE) ratio of 27.99, marking a new low in 48 days [1] - The total market capitalization of the company is 8.642 billion yuan [1] - In terms of capital flow, on June 9, the company saw a net inflow of 3.2614 million yuan, with a total inflow of 10.0675 million yuan over the past five days [1] Industry Comparison - The average PE ratio for the chemical products industry is 43.87, with a median of 39.46, positioning the company at 81st in the industry ranking [2] - The company's static PE is 24.71, and its price-to-book ratio is 2.33 [2]

北 京 大成 律师 事 务所 关 于 博 爱 新开 源医 疗 科技 集团 股 份有 限公 司 2024 年 年 度股 东 大会 之 法 律 意见 书 Tel: +86 10-58137799 Fax: +86 10-58137788 北京大成律师事务所 北 京 大 成 律 师 事 务 所 www.dentons.cn 北京市朝阳区朝阳门南大街 10 号兆泰国际中心 B 座 16-21 层 16-21F, Tower B, ZT INTERNATIONAL CENTER, No.10, Chaoyangmen Nandajie, Chaoyang District, Beijing 关于博爱新开源医疗科技集团股份有限公司 2024 年年度股东大会之法律意见书 致：博爱新开源医疗科技集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会《上市公司 股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范性文 件的要求，北京大成律师事务所（以下简称"本所"）接受博爱新开源医疗科技集 团股份有限公司（以下简称" ...